second-line treatment of elderly patients with epithelial ovarian carcinoma . Cancer 2002 ; 94 : 1961 – 1967 . 10.1002/cncr.10385 11932898 2. Jang RW , Caraiscos VB , Swami N , . Simple prognostic model for patients with advanced cancer based
Search Results
Performance Status Restriction in Phase III Cancer Clinical Trials
Joseph Abi Jaoude, Ramez Kouzy, Walker Mainwaring, Timothy A. Lin, Austin B. Miller, Amit Jethanandani, Andres F. Espinoza, Dario Pasalic, Vivek Verma, Noam A. VanderWalde, Benjamin D. Smith, Grace L. Smith, C. David Fuller, Prajnan Das, Bruce D. Minsky, Claus Rödel, Emmanouil Fokas, Reshma Jagsi, Charles R. Thomas Jr, Ishwaria M. Subbiah, Cullen M. Taniguchi, and Ethan B. Ludmir
Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 1.2014
Mary B. Daly, Robert Pilarski, Jennifer E. Axilbund, Saundra S. Buys, Beth Crawford, Susan Friedman, Judy E. Garber, Carolyn Horton, Virginia Kaklamani, Catherine Klein, Wendy Kohlmann, Allison Kurian, Jennifer Litton, Lisa Madlensky, P. Kelly Marcom, Sofia D. Merajver, Kenneth Offit, Tuya Pal, Boris Pasche, Gwen Reiser, Kristen Mahoney Shannon, Elizabeth Swisher, Nicoleta C. Voian, Jeffrey N. Weitzel, Alison Whelan, Georgia L. Wiesner, Mary A. Dwyer, and Rashmi Kumar
hamartoma-tumor syndrome . Arch Dermatol 2006 ; 142 : 625 – 632 . 28. Jazaeri AA Lu K Schmandt R . Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma . Mol Carcinog 2003 ; 36 : 53 – 59 . 29
Determining Chemotherapy Tolerance in Older Patients With Cancer
Jerome Kim and Arti Hurria
: 3457 – 3465 . 9. Freyer G Geay JF Touzet S . Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: a GINECO study . Ann Oncol 2005 ; 16 : 1795 – 1800
The Cost of Initial Care for Medicare Patients With Advanced Ovarian Cancer
Renata R. Urban, Hao He, Rafael Alfonso-Cristancho, Melissa M. Hardesty, and Barbara A. Goff
Wiechert A . Patient, treatment and discharge factors associated with hospital readmission within 30 days after surgical cytoreduction for epithelial ovarian carcinoma . Gynecol Oncol 2013 ; 130 : 407 – 410 . 27. FDA Draft Guidance on
Management of Chemotherapy-Induced Neutropenia: Measuring Quality, Cost, and Value
Michaela A. Dinan, Bradford R. Hirsch, and Gary H. Lyman
epithelial ovarian carcinoma—a cost-effectiveness analysis . Int J Gynecol Cancer 2007 ; 17 : 1019 – 1024 . 38. Fust K Li X Maschio M . Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent
DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development
Talia Golan and Milind Javle
response and progression-free survival were demonstrated when treated with checkpoint inhibitors. 45 BRCA1/2 mutated high-grade serous ovarian carcinoma is associated with a higher mutation burden compared with non– BRCA1/2 -mutated tumors, higher
Extending Comprehensive Cancer Center Expertise in Clinical Cancer Genetics and Genomics to Diverse Communities: The Power of Partnership
Deborah J. MacDonald, Kathleen R. Blazer, and Jeffrey N. Weitzel
Yap TA . Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers . N Engl J Med 2009 ; 361 : 1 – 12 . 12. Lynch HT Casey MJ Snyder CL . Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology
Risk Assessment and Prophylaxis for VTE in Cancer Patients
Alok A. Khorana
-bearing microparticles are associated with venous thromboembolic events in malignancy . Clin Cancer Res 2009 ; 15 : 6830 - 6840 . 24 Han LY Landen CN Jr Kamat AA . Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian
Biologics in Cervical Cancer Therapy
Lyndsay J. Willmott, Daniele A. Sumner, and Bradley J. Monk
is a monoclonal antibody directed against VEGF-A. It was the first clinically available antiangiogenic agent in the United States 19 and has been successfully studied in many solid tumors, including colon, lung, breast, renal, brain, and ovarian
Resurrection of PARP Inhibitors in Breast Cancer
Tomas G. Lyons and Mark E. Robson
. 13. Gelmon KA Tischkowitz M Mackay H . Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study . Lancet Oncol
